

**Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer****THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Approximately what proportion of metastatic colorectal cancer (mCRC) cases are HER2 amplified?**
  - Less than 1%
  - 3% to 5%**
  - 25% to 30%
  - More than 50%
- 2. Which of the following proteins is targeted by adagrasib?**
  - HER2
  - EGFR
  - KRAS G12C**
  - NTRK
- 3. What was the approximate response rate for the HER2 IHC 1+ cohort of patients with mCRC in the Phase II DESTINY-CRC01 trial?**
  - 60%
  - 40%
  - 20%
  - 0%**
- 4. Fruquintinib inhibits which of the following targets?**
  - KRAS
  - VEGF**
  - PD-1
  - HER3
- 5. Which of the following statements best describes results of the Phase II ReDOS study evaluating standard dosing of regorafenib versus dose escalation for patients with refractory mCRC?**
  - No difference in the proportion of patients starting cycle 3 was observed between the study arms
  - More patients started cycle 3 in the dose-escalation arm**
  - More patients started cycle 3 in the standard-dose arm